Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial

BACKGROUND: The phase II AFUGEM GERCOR trial aimed to assess the efficacy of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine (gemcitabine group) or simplified leucovorin and fluorouracil (sLV5FU2 group) in patients with previously untreated metastatic pancreatic cancer. Results...

Descripción completa

Detalles Bibliográficos
Autores principales: Charton, Emilie, Bachet, Jean‐Baptiste, Hammel, Pascal, Desramé, Jérôme, Chibaudel, Benoist, Cohen, Romain, Debourdeau, Philippe, Dauba, Jérome, Lecomte, Thierry, Seitz, Jean‐François, Tournigand, Christophe, Aparicio, Thomas, Guerin‐Meyer, Véronique, Taieb, Julien, Volet, Julien, Louvet, Christophe, Anota, Amélie, Bonnetain, Franck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718524/
https://www.ncbi.nlm.nih.gov/pubmed/31314957
http://dx.doi.org/10.1002/cam4.2311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718524/
https://www.ncbi.nlm.nih.gov/pubmed/31314957
http://dx.doi.org/10.1002/cam4.2311

Ejemplares similares